Oncology Institute (TOIIW) Change in Receivables (2021 - 2026)

Oncology Institute has reported Change in Receivables for 6 years, with the latest figure at -$864000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables changed N/A year-over-year to -$864000.0; the trailing twelve-month figure through Mar 2026 stood at $11.4 million (up 85.84% YoY), and the FY2025 full-year result was $12.3 million, up 105.99% from the prior year.
• Change in Receivables for Q1 2026 stood at -$864000.0, down from -$641000.0 in the prior quarter.
• The five-year high for Change in Receivables was $21.0 million in Q4 2022, with the low at -$6.2 million in Q4 2024.
• Historically, Change in Receivables has averaged $2.6 million across 5 years, with a median of $59500.0 in 2022.
• The largest YoY upside for Change in Receivables was 4331.92% in 2022 against a maximum downside of 540.11% in 2022.
• Oncology Institute's Change in Receivables stood at $21.0 million in 2022, then plunged by 119.52% to -$4.1 million in 2023, then tumbled by 50.67% to -$6.2 million in 2024, then soared by 89.61% to -$641000.0 in 2025, then slumped by 34.79% to -$864000.0 in 2026.
• The last three Change in Receivables figures came in at -$864000.0 (Q1 2026), -$641000.0 (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.